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 Objective To investigate the diagnostic performance and safety of 
endobronchial ultrasound-guided transbronchial needle 
aspiration in patients presenting with radiological features of 
lung cancer. 
 Design Prospective case series.
 Setting University teaching hospital, Hong Kong.
 Patients Consecutive patients with mediastinal or hilar abnormalities 
suspected of or confirmed as having lung cancer underwent 
endobronchial ultrasound-guided transbronchial needle 
aspiration and presented between August 2006 and December 
2010.
 Main outcome measures Diagnostic performance (including sensitivity, specificity, negative 
predictive value and accuracy), procedural complications, and 
tissue adequacy for molecular profiling.
 Results A total of 269 procedures were performed in 259 patients, 
with malignancy confirmed in 210 (81%) of them. In the whole 
cohort with confirmed or suspected lung cancer, the overall 
sensitivity, specificity, negative predictive value, and accuracy 
of endobronchial ultrasound-guided transbronchial needle 
aspiration were 87%, 100%, 74%, and 91%, respectively. Among 
42 patients with tumour samples sent for mutation tests 
(epidermal growth factor receptor and/or anaplastic lymphoma 
kinase), 40 (95%) were found to be adequate. No complication 
or mortality ensued from these procedures.
 Conclusion Endobronchial ultrasound-guided transbronchial needle 
aspiration is highly effective in determining the diagnosis and 
lymph node staging in patients with lung cancer. In combination 
with its excellent safety profile, it should be considered a 
frontline diagnostic test for patients presenting with mediastinal 
abnormalities suspicious of lung cancer.
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When there is an abnormal lung lesion evident on radiological examination, the next step 
is to establish the diagnosis and accurately determine its stage if lung cancer is suspected. 
Both computed tomography (CT) and positron emission tomography (PET) are effective in 
localising the primary lesion and any metastatic foci. However, pathological confirmation 
remains the gold standard, especially in Hong Kong, where tuberculosis is endemic and 
not uncommonly masquerades as malignancy. 
 Conventional flexible fibreoptic bronchoscopy (FOB) is useful in the diagnosis 
of endobronchial lesions, but many lung cancers are extraluminal and thus invisible 
New knowledge added by this study
• Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) carries high 
diagnostic accuracy for lung cancer in Hong Kong.
• The safety of EBUS-TBNA has been well-demonstrated in our local setting.
Implications for clinical practice or policy













during bronchoscopy. Because of the extensive 
branching and angulation of the lower bronchial 
tree, the diagnostic yield of FOB coupled with 
fluoroscopy-guided transbronchial lung biopsy 
(TBLB) is still suboptimal for parenchymal lung 
lesions, and depends on the lesion’s size and 
location. Conventional transbronchial needle 
aspiration (TBNA) without image guidance has high 
diagnostic yield for lesions adjacent to the airway, 
but has been underutilised in most parts of the world 
including Hong Kong, partly due to reported serious 
complications such as bleeding and pneumothorax.1-3 
Alternatively, CT-guided needle aspiration is useful in 
the diagnosis of peripheral lung lesions but carries 
significant risks of a pneumothorax (25%) and having 
a chest tube inserted (5%).4,5 Pathological lymph node 
staging of the mediastinum remains unattainable 
with both TBLB and CT-guided needle biopsy. 
 Recently, endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA) 
has been shown to be a highly accurate and safe 
procedure for the diagnosis and staging of patients 
with confirmed or suspected lung cancer.6,7 The 
procedure can be incorporated with conventional 
FOB in a single bronchoscopic session using local 
anaesthesia. This can provide adequate tissue to 
assess epidermal growth factor receptor (EGFR) 
mutation status to guide treatment with modern 
targeted oral therapeutic agents.8 Since the first 
introduction of EBUS-TBNA in Hong Kong in 2005, 
the technology has now become widely available 
in the community. As pioneers in adopting this new 
technology locally, we describe the first experience 
of EBUS-TBNA in Hong Kong and discuss its role in 
comparison with currently available alternatives. 
 Thus, the aim of this study was to define the 
overall diagnostic performance of EBUS-TBNA in 
the setting of suspected or confirmed lung cancer, 
as well as according to the final diagnoses including 
malignancy and infection. The performance of EBUS-
TBNA as the first pathological diagnostic test was also 
defined.
Methods
Recruitment and procedure of endobronchial 
ultrasound-guided transbronchial needle 
aspiration
This study was performed prospectively between 
August 2006 and December 2010, allowing at least 1 
year of clinical follow-up at the time of analysis. Queen 
Mary Hospital was the first centre in Hong Kong that 
provided EBUS-TBNA with the approval from the 
Hospital Authority. All patients having confirmed 
or suspected lung cancer referred for EBUS-TBNA 
with enlarged (short diameter >1 cm) mediastinal/
























airways on CT (with or without PET confirmation) were 
recruited. If the target lesion was subcentimetre on 
CT and yet 18F-fluorodeoxyglucose avid on PET, EBUS-
TBNA was also considered. All the procedures were 
performed by a chief operator (MKW) who received 
relevant training in year 2005 and launched the EBUS-
TBNA service in Queen Mary Hospital from 2006. The 
abnormal lymph node stations as detected by CT scan 
and/or PET were taken as reference. If more than one 
lymph node station was involved, the procedure was 
performed in the order N3 to N1 node, according to 
the seventh edition of the American Joint Committee 
on Cancer cancer staging manual. Contra-indications 
and preparations were the same as for patients 
undergoing FOB with biopsy intent, and included 
having a medically unstable condition, bleeding 
diathesis, and lack of consent. The procedures were 
performed under conscious sedation with midazolam 
and pethidine used intravenously, in addition to local 
anaesthesia. The specially designed EBUS scope 
(XBFUC260F-OL8; Olympus, Tokyo, Japan) had the 
curvilinear transducer incorporated at the tip with 
an outer diameter of 6.7 mm. It was administered 
trans-orally. A saline-inflated balloon kept the probe 
in contact with the bronchial wall while sampling the 
lymph node. The system had an integrated colour 
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Doppler function, with enhanced visualisation of 
blood vessels to prevent inadvertent puncturing. 
A dedicated 22-gauge fine needle was deployed to 
perform TBNA under direct visualisation, so that 
the excursion of the needle within the lesion could 
be maximised and large histological cores could 
be obtained. Rapid-on-site cytological examination 
(ROSE) was not available in our centre and the 
procedure was stopped if no satisfactory specimen 
was obtained after five needle passes per lesion. 
All specimens were sent for histological (preserved 
in 10% buffered formalin), cytological (fixed in 50% 
alcohol), and microbiological examinations (acid-
fast bacilli and fungi). Molecular profiling, namely 
EGFR mutation tests, were analysed for those with 
confirmed adenocarcinoma from October 2008 when 
the test became commonly adopted. Conventional 
FOB was carried out if indicated. Chest radiography 
was performed after the patients were transferred 
back to the wards to exclude pneumothorax. 
Procedure-related complications such as excessive 
bleeding, infection, pneumothorax, and respiratory 
failure warranting intervention were to be recorded. 
 Written informed consent was obtained from 
all study patients, and the study was approved by the 
Institutional Review Board of the University of Hong 
Kong/Hospital Authority Hong Kong West Cluster 
(HKU/HA HKW IRB: UW 06-236T/1261).
Statistical analyses
In this study, diagnostic performance was procedure-
based. A positive result was defined if a specific 
diagnosis (eg carcinoma or tuberculosis) was made, 
without the need for surgical diagnostic intervention. 
A negative result referred to proceeding to further 
investigation (eg mediastinoscopy or thoracotomy), 
which was always undertaken unless the patient 
was unfit for such a procedure or declined it. A 
false-negative result was defined as no specific 
diagnosis until further investigation yielded 
positive findings from the target area or follow-up 
eventually confirmed a positive diagnostic result in 
the area of interest. True negative was defined as a 
biopsy being confirmed as negative after surgical 
exploration, or unremarkable follow-up for at least 1 
year. The diagnostic yield including sensitivity (true 
positives/[true positives + false negatives]), negative 
predictive value (true negatives/[true negatives + 
false negatives]), and accuracy ([true positives + 
true negatives]/[true positives + true negatives + 
false positives + false negatives]) were calculated. 
Taking the pathological or microbiological diagnosis 
revealed by EBUS-TBNA as the gold standard, false 
positives were assumed to be absent.
 Skewed continuous and normally distributed 
variables were presented as medians (ranges), and 
means and standard deviations (SDs), respectively. 
Results
Clinical and demographic characteristics
Over the study period of 4 years and 4 months, 
there were 269 EBUS-TBNAs performed in 259 
patients, which included three who had repeat 
procedures to confirm the diagnosis. Seven patients 
who had first EBUS-TBNA–confirmed lung cancer 
underwent mediastinal restaging by EBUS-TBNA after 
neoadjuvant therapy. The median age of these 259 
patients was 62 (range, 24-86) years; all were Asians 
and there was a predominance of males (63%). The 
TABLE 1.  Characteristics of 259 patients undergoing endobronchial ultrasound-
guided transbronchial needle aspiration (EBUS-TBNA)
TABLE 2.  Characteristics of 269 lesions sampled by 
endobronchial ultrasound-guided transbronchial needle 
aspiration*
Characteristic Median (range) or 
No. (%) of patients




Final diagnosis of malignancy 210 (81%)
Diagnosed by EBUS-TBNA 158 (75%)
No. of patients with underlying malignancy 95 (37%)
Lung cancer, previously treated 26 (27%)
Head and neck cancer 23 (24%)
Breast cancer 20 (21%)
Gastro-intestinal cancer 13 (14%)
Urological cancer 8 (8%)
Hepatocellular carcinoma 6 (6%)
Gynaecological cancer 5 (5%)
Lymphoma 4 (4%)
Duration of malignancy prior to EBUS-TBNA (years) 3.8 (0-32)
Characteristic Mean ± SD or  
No. (%) of patients
Lymph node size on CT scan (cm) 1.36 ± 0.61
Lymph node sites with sample taken
Mediastinal 231 (86%)
Right paratracheal 158 (59%)
Left paratracheal 52 (19%)
Subcarinal 165 (61%)
Hilar/interlobar 94 (35%)
Lung lesion size in long diameter (cm) 5.0 ± 3.0
Lung lesion sampled 38 (14%)
No. of needle passes per site 2.69 ± 1.11
No. of sites sampled per patient 2.00 ± 1.00
* CT denotes computed tomography, and SD standard deviation
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prevalence of confirmed malignancy in this cohort 
was 81% (210 patients), among whom malignancy 
was revealed in specimens obtained by EBUS-TBNA 
in 158 (75%; Table 1). The characteristics of the lesions 
sampled are shown in Table 2. Regarding the 269 
EBUS-TBNA procedures performed, 38 (14%) had lung 
lesions sampled, of which 29 (76%) were found to be 
diagnostic. Whereas, 231 (86%) of these procedures 
entailed mediastinal lymph node sampling and 94 
(35%) entailed hilar/interlobar lymph node sampling. 
The right paratracheal and subcarinal lymph nodes 
were the most commonly sampled, and accounted 
for 59% and 61% of all such sampling, respectively 
(Fig 1).9 The size of the lymph nodes sampled had 
a mean diameter of 1.36 cm (SD, 0.61 cm). Before 
their EBUS-TBNA procedure, results from PET were 
only available in 122 (45%) of the patients. Among 
the group with non-diagnostic EBUS-TBNA findings, 
there were 30 patients who underwent subsequent 
surgical exploration, and three had a second EBUS-
TBNA. The remaining 60 patients were clinically 
followed up only. Among the latter, there were 33 with 
no evidence of malignancy during a mean follow-up 
duration of 1.7 (SD, 1.3) years (Fig 2).
FIG 1.  Computed tomographic scans of the typical location of lymph nodes sampled by endobronchial ultrasound-guided 
transbronchial needle aspiration
Based on the 7th edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer9: (a) 4R denotes right lower paratracheal 
lymph node, and 4L left lower paratracheal lymph node. (b) 7 denotes subcarinal lymph node. (c) 11R denotes right interlobar lymph 
node, and 11L left interlobar lymph node
FIG 2.  Flowchart for patients with suspected lung cancer with enlarged mediastinal lymph nodes who underwent endobronchial 
ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and follow-up. Patients were categorised by final diagnoses
* Including 7 patients with repeat EBUS-TBNA for restaging after neoadjuvant therapy. After restaging by second EBUS-TBNA and 
confirmed by surgery, 4 of them were true positives, 2 were true negatives, and 1 was false negative
† FN and TN refer to the outcome of the first EBUS-TBNA; FN denotes false negative, and TN true negative
‡ Confirmed no pathological lymph node at surgery. Final diagnosis of malignancy confirmed in lung or other primary sites
§ Confirmed active pulmonary tuberculosis with reactive lymph node at surgery
❘❘ Confirmed malignancy in primary sites (lung, head, and neck) and received local radiotherapy. Previous EBUS-TBNA sampled lymph 
nodes showed no interval change during clinical follow-up
259 Patients underwent EBUS-TBNA
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The diagnostic performance of these 269 EBUS-
TBNA procedures resulted in a sensitivity, specificity, 
negative predictive value, and accuracy of 87% 
(173/[173+25]), 100%, 74% (71/[71+25]), and 91% 
([173+71]/269), respectively. In the 220 procedures 
yielding a final diagnosis of malignancy, the respective 
sensitivity and negative predictive values were 89% 
(162/[162+20]) and 66% (38/[38+20]). Regarding the 
lesions that turned out to be infections (10 cases of 
tuberculosis and 1 of cryptococcosis), though lung 
cancer was suspected initially, the sensitivity and 
negative predictive values were 75% (6/[6+2]) and 60% 
(3/[3+2]), respectively. Regarding EBUS-TBNA used as 
the first diagnostic test (ie for tissue sampling), there 
were 158 procedures that yielded sensitivity and 
negative predictive values of 90% (100/[100+11]) and 
81% (47/[47+11]), respectively (Table 3). 
 In all, 95 (37%) of the patients had a pre-
existing malignancy diagnosed with a median of 3.8 
years before the EBUS-TBNA. In 27 (28%) of these 
individuals, the pathology revealed by the procedure 
was other than that of the pre-existing one. 
Molecular profiling and histological classification
When EBUS-TBNA was introduced locally in 2006, 
molecular profiling such as for EGFR and anaplastic 
lymphoma kinase (ALK) was not widely accepted 
as standard practice. It was not until October 2008 
that molecular profiling was included as routine 
when adenocarcinoma was diagnosed by EBUS-
TBNA. Subgroup analysis was therefore performed 
to determine whether EBUS-TBNA was a reliable 
diagnostic tool for retrieving adequate tissue for 
EGFR or ALK mutation tests. Among 40 patients 
with samples sent for EGFR and/or ALK, 38 (95%) 
were found to be adequate. Among these, 24 (60%) 
harboured mutations in the EGFR gene exons 18-21 
as detected by polymerase chain reaction and DNA 
sequencing and 13 (33%) were negative (wild-type), 
and one had the ALK translocation. 
 Apart from the origin of the tumour, it is now 
considered imperative to know the cell type within 
non–small-cell lung cancer (NSCLC) as chemotherapy 
may then be individualised. Of the 158 patients 
confirmed to have malignancy by EBUS-TBNA, 
only 22 (14%) were revealed to be NSCLC without 
information about the exact cell type, differentiation 
of the tumour, EGFR status, or primary origin of the 
tumour. 
Complications
Regarding all 269 procedures performed, there 
were no significant complications (bleeding, 
pneumothorax, infection, or respiratory distress) 
warranting reversal of sedation or any other 
intervention. All the patients, including 14 with 
superior vena caval obstruction and 1 with severe 
heart failure (left ventricular ejection fraction 20%), 
tolerated the procedures well and no procedure was 
prematurely terminated. 
Discussion
Most patients with lung cancer are in locally advanced 
or metastatic stages upon diagnosis and proper 
staging is important in classifying patients into 
operable or inoperable status.10,11 In the absence of 
distant metastases, mediastinal lymph node staging 
remains the most important factor determining 
overall staging. Sampling of mediastinal lymph 
nodes is therefore important in both diagnosis and 
staging, which should guide subsequent treatment. 
The term ‘personalised therapy’ is coined in contrast 
with that in the past, when treatment for lung cancer 
was mainly classified into small-cell lung cancer or 
NSCLC only. Nowadays, among advanced stages 
of NSCLC, oral targeted therapy (EGFR tyrosine 
kinase inhibitor) is considered the preferred first-
line treatment in the presence of EGFR mutations 
in exon 19 and 21.12 Falling short of this, specific 
anti-cancer therapeutic options (chemotherapy 
and anti-angiogenic agents) are currently decided 
* CI denotes confidence interval
TABLE 3.  Diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)





























according to the carcinoma cell types, namely: small, 
large, adeno, or squamous.13-15 In patients with pre-
existing malignancy, subsequent treatment is largely 
dictated by differentiating metastatic disease from 
primary carcinoma of the lung. Based on our 4-year 
experience since 2006, EBUS-TBNA has demonstrated 
high diagnostic accuracy in providing clear-cut 
histological classification and molecular profiling 
that facilitated state-of-the-art treatment for lung 
cancer.
 Previously, surgical intervention such as 
mediastinoscopy was the only diagnostic modality 
with access to the mediastinal lymph nodes for tissue 
sampling, though the hilar area remained a sanctuary 
site. However, surgical exploration is not usually 
considered the upfront diagnostic investigation, due 
to the need for general anaesthesia for which most 
patients with advanced lung cancer are not good 
candidates. Recourse to EBUS-TBNA opens a new 
diagnostic paradigm for patients having mediastinal 
or hilar lymphadenopathy. In our study, its diagnostic 
yield was close to 90%, which is similar to most 
clinical series reported worldwide.5,6 A negative result 
from EBUS-TBNA (with the negative predictive value 
of 74% only), however, warrants further investigation 
and may be best explained by the sampling error 
associated with a fine needle. 
 The advantage of using EBUS-TBNA with a 22-G 
fine needle for sampling under real-time guidance 
is that it minimises inadvertent puncturing of blood 
vessels by the Doppler mode screening. This was 
exemplified by the excellent safety demonstrated in 
our series. Regrettably, ROSE was not available in our 
centre, but has the potential to reduce the number 
of needle passes and sites sampled per patient, and 
hence the complication rate. The procedural time 
was not recorded but was estimated to be around 
20 to 50 minutes, depending on the number of 
lesions sampled. Recently, we have shown that EBUS-
TBNA was safe even in patients with superior vena 
caval obstruction.16 Using the fine needle does not 
jeopardise securing adequate pathological data 
required for formulating personalised treatment. Of 
the 210 patients confirmed as having malignancy as 
their final diagnosis, EBUS-TBNA was able to detect 
extrathoracic malignancy in 23 (11%) and primary 
lung cancer in 135 (64%). Among those 135 patients 
with confirmed primary lung cancer, 118 (87%) had 
the exact cell type delineated, although this could 
have been confounded by concomitant changes in 
the pathological classification and management of 
NSCLC during the study period. For the 40 patients 
who had molecular profiling, adequate tissues for 
EGFR or ALK mutation tests were obtained in 38 
(95%), which was much higher than the 36% reported 
in a recent landmark clinical trial on targeted 
therapy (IPASS study) using conventional diagnostic 
methods.17 Moreover, EBUS-TBNA is useful in the 
diagnosis of synchronous lung cancers and other 
benign conditions affecting the mediastinum such as 
tuberculosis, fungal infection, or sarcoidosis.18-21 
 Endoscopic ultrasound-guided fine-needle 
aspiration (EUS-FNA), via the trans-oesophageal 
approach, was developed earlier than EBUS-TBNA and 
is also reported to have high diagnostic performance 
in mediastinal lymphadenopathy. However, EUS-FNA 
provides limited access to the hilum and the right 
side of the mediastinum. Although the inferior 
mediastinal nodal stations such as para-oesophageal 
(below the carina) and pulmonary ligament can 
be approached by EUS-FNA but not EBUS-TBNA, 
metastatic involvement in these areas is relatively 
uncommon. In a local study, it only accounted for 
about 6% of lymph nodes sampled by EUS-FNA.22 
Nevertheless, the combination of EBUS-TBNA and 
EUS-FNA has even better diagnostic performance 
than either procedure alone.23 However, whether this 
combined approach can replace mediastinoscopy is 
yet to be elucidated. 
 In summary, EBUS-TBNA has been shown to have 
high diagnostic performance and excellent safety. 
Similar to other technical procedures, it requires a 
defined period of training. Due to the steep learning 
curve at the beginning, some professional bodies 
have recommended a minimum requirement of 25 
procedures be performed annually to maintain the 
technical skill for EBUS proficiency.24 The diagnostic 
yield was also associated with annual hospital EBUS-
TBNA volume and reflects the combined team 
experience, and also involves anaesthetic use and 
cytopathological interpretation.25-27
 In Hong Kong, EBUS-TBNA has been introduced 
for the past 7 years, and has emerged as an important 
tool in the field of interventional pulmonology, which 
is rapidly evolving worldwide. The management of 
lung cancer is greatly advanced with all these new 
diagnostic and therapeutic modalities in the pipeline, 
underscoring the importance of personalised 
therapy, which is the new paradigm. 
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